Bluebird Bio Inc. started an underwritten public offering for $600 million of its common stock.
The company will grant the underwriters an option to buy up to an additional 15% of the common shares offered.
Goldman Sachs & Co. LLC, Bank of America Merrill Lynch, J.P. Morgan Securities LLC and Cowen are acting as joint book-running managers of the proposed offering.
